Document Detail

Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy.
MedLine Citation:
PMID:  15240607     Owner:  NLM     Status:  MEDLINE    
A retrospective comparison was performed between 1411 hypopituitary adults without GH replacement [mean age, 56.9 (sd 18.6) yr] and the normal population in terms of fatal and nonfatal morbidity. A similar prospective comparison was then made in 289 hypopituitary patients on long-term GH replacement [mean age, 47.6 (sd 14.8) yr; mean duration of GH treatment, 60 months]. In the 1411 hypopituitary patients without GH replacement, overall mortality (P < 0.001), and the rates of myocardial infarctions (P < 0.01), cerebrovascular events (P < 0.001), and malignancies (P < 0.001) were increased compared with the normal population. Colorectal cancer was the most common malignancy in this cohort (P < 0.001 vs. the background population). In the 289 hypopituitary patients on GH replacement, overall mortality and the rate of malignancies were similar to the normal population. In the hypopituitary adults on GH therapy, the rate of myocardial infarctions was lower than that in the background population (P < 0.05), and there was a tendency toward an increased rate of cerebrovascular events. In conclusion, overall mortality and the rate of myocardial infarctions were increased in hypopituitary patients without GH replacement. An increased rate of malignancies was observed in the hypopituitary adults without GH therapy, with a predominance of colorectal cancer. GH replacement appeared to provide protection from myocardial infarctions. The rate of cerebrovascular events tended to be increased also in hypopituitary adults on GH therapy.
J Svensson; B-A Bengtsson; T Rosén; A Odén; G Johannsson
Related Documents :
12601287 - Regression of left ventricular hypertrophy after aortic valve replacement in patients o...
16275007 - Importance of implant technique on risk of major paravalvular leak (pvl) after st. jude...
18085217 - In vitro heart valve tissue engineering.
15905337 - Stentless vs. stented aortic valve replacement: left ventricular mass regression.
17098797 - Panoramic optical mapping reveals continuous epicardial reentry during ventricular fibr...
15944097 - Cardiac resynchronisation therapy versus dual site right ventricular pacing in a patien...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  89     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2004 Jul 
Date Detail:
Created Date:  2004-07-08     Completed Date:  2004-08-10     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3306-12     Citation Subset:  AIM; IM    
Research Centre for Endocrinology and Metabolism, Gröna Stråket 8, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / epidemiology,  etiology*,  mortality
Colorectal Neoplasms / epidemiology,  etiology
Hormone Replacement Therapy*
Human Growth Hormone / therapeutic use*
Hypopituitarism / complications*,  drug therapy*
Middle Aged
Myocardial Infarction / epidemiology,  etiology,  prevention & control
Neoplasms / epidemiology,  etiology*,  mortality
Prospective Studies
Recombinant Proteins / therapeutic use
Retrospective Studies
Reg. No./Substance:
0/Recombinant Proteins; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Longitudinal study on growth and body mass index before and after diagnosis of childhood craniophary...
Next Document:  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hy...